A Study on the Operational Efficiency of Selected Pharmaceutical Companies in India

Abstract

The Indian pharmaceutical industry has emerged as a significant contributor to the global healthcare market because of its innovation, cost efficiency, and expanding production capacity. This study analyzes the financial and operational performances of ten leading pharmaceutical companies in India—Cipla, Sun Pharmaceutical Industries, Aurobindo Pharma, Dr. Reddy’s Laboratories, Cadila Pharmaceuticals, Glaxo Smith Kline Pharmaceuticals Ltd, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Lupin Limited, and Ranbaxy Laboratories—during the period 2012–13 to 2021–22. The primary objective was to evaluate their financial efficiency and operational performance using various accounting and statistical measures. The study is based on secondary data collected mainly from the PROWESS database of the Centre for Monitoring Indian Economy (CMIE), along with information from the Bombay Stock Exchange and other reliable sources. Financial performance was assessed through ratio analysis covering profitability, liquidity, solvency, asset utilisation, and working capital efficiency. Statistical techniques, such as mean, standard deviation, variance, skewness, kurtosis, and compound annual growth rate (CAGR), correlation, and regression analysis, were applied using Microsoft Excel and SPSS.
The results reveal that the selected companies exhibit satisfactory overall financial performance, although moderate fluctuations are observed across the study period. Cipla records the highest mean production and sales performance, indicating its dominant market position, while Glenmark Pharmaceuticals demonstrates the highest growth rate. Stability in production is observed in Glaxo Smith Kline Pharmaceuticals Ltd. and Ranbaxy Laboratories, whereas higher variability is found in Torrent Pharmaceuticals and Lupin Limited. Regression analysis further indicates that company size, growth, GDP, leverage, and cash conversion cycle significantly influence liquidity This study assesses the profitability of the Indian pharmaceutical industry. It helps companies and investors understand its financial efficiency. It aims to help management identify its financial problems at present and the specific areas in the business that might need some effort for more effective and efficient utilisation of its resources. The study concludes that efficient asset utilisation, improved sales performance, and increased investment are crucial for sustaining long-term growth and competitiveness in the Indian pharmaceutical industry.